I graduated from Newcastle University and following basic surgical training, was a recipient of a CRUK PhD studentship and subsequently the first surgeon to be awarded a CRUK Clinician Scientist Fellowship.
My research has covered the full spectrum of basic science, translational, clinical and epidemiological disciplines in prostate cancer. My laboratory work as group leader led to novel discoveries into the pivotal role of endogenous signalling regulators (SEF/SPRED) in prostate cancer and mechanistic insights into growth factor signalling in disease progression and treatment resistance. In recent years my work has focused increasingly on the translational/clinical interface and the application of research findings into clinical practice.
I have developed and implemented novel prognostic prediction models for both group stratified cohorts Cambridge Prognostic Groups and for individualised prediction Predict Prostate for personalised management of prostate cancer. These models have been shown to outperform current guideline endorsed risk models and have been adopted into local and regional guidelines. Predict prostate is the only decision aid endorsed by the UK NICE National Guidelines on prostate cancer. I have pioneered risk stratified pathways for active surveillance follow up and setup one of the first dedicated surveillance clinics for early disease monitoring. I have developed and led numerous investigator led multicentre clinical trials including TAPS01, Predict Prostate RCT, PRIM biomarker study, and the NIHRi4i funded CAMPROBE study (based on his own invention of a new simple device for infection free prostate biopsies).
My work has been cited in prostate cancer guidelines by NICE and the European Association of Urology. To further interdisciplinary research in prostate cancer he established the Translational Prostate Cancer Group (TPCG) in Cambridge with colleagues from urology, oncology, radiology, pathology and basic science. The TPCG have so far collaborated on >60 peer reviewed papers with a combined grant income of >£6M. I have also established links with STEM scientists to develop biosensors for cancer detection across different platforms. I am also Chief Investigator of the DIAMOND study which hold over 3000 bio-samples, tissue and annotated clinical data for biomarker discovery in urological diseases (to date used in over 50 research studies).